Drug Trial Radar · NCT07191483
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
149
Actual
Start
Aug 27, 2025
Primary completion
Sep 9, 2026
Study completion Sep 16, 2026
Sponsor
- Lead sponsor
- Kynexis B.V.Industry
- Sponsor type
- Industry
- First posted
- Sep 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of 3 different dose regiments of KYN-5356 and placebo for 28 days. Participants will be randomized to one of 4 treatment groups: placebo, KYN-5356 low dose, KYN-5356 medium dose, KYN-5356 high dose. Participants will be admitted to the clinic on Day -3 and will remain in residence at the clinic for 32 days, from baseline through the treatment period. Participants will be administered investigational medicinal product on Days 1 through 28. Efficacy, safety, PK and exploratory PD assessments will be performed throughout the dosing period. Participants will be discharged on Day 29 after safety assessments are completed and return for a follow-up visit on Day 42. A subset of participants from selected sites will undergo electrophysiological assessments to evaluate the effect of KYN-5356 on neurophysiological measures of brain function.
Conditions
- Cognitive Impairment Associated With Schizophrenia (CIAS)
Interventions
KYN-5356 low doseDrug
oral tablet
PlaceboOther
Oral tablet
KYN-5356 Medium DoseDrug
oral tablet
KYN-5356 High DoseDrug
oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the efficacy of KYN-5356 treatment on cognitive function in adults with cognitive impairment associated with schizophrenia (CIAS)Time frame: 28 days
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Woodland International Research Group
Little Rock, Arkansas
Synapse Clinical Trials
Cerritos, California
Synergy Research Center
Lemon Grove, California
Cenexel CNS
Los Alamitos, California
NeuroBehavioral Hospitals of the Palm Beaches - South
Boynton Beach, Florida
Cenexel RCA
Hollywood, Florida
Segal Trials
Miami Lakes, Florida
Cenexel ACMR
Atlanta, Georgia
Cenexel iResearch Atlanta
Decatur, Georgia
Uptown Research Institute
Chicago, Illinois
Cenexel CBH
Gaithersburg, Maryland
Arch Clinical Trials
St Louis, Missouri
Cenexel HRI
Marlton, New Jersey
Neuro-Behavioral Clinical Research
North Canton, Ohio
Community Clinical Research
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.